ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 183 filers reported holding ACADIA PHARMACEUTICALS INC in Q3 2015. The put-call ratio across all filers is 1.98 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2017 | $117,539,000 | +20.1% | 3,418,861 | +0.8% | 0.10% | +17.1% |
| Q4 2016 | $97,834,000 | -3.8% | 3,392,171 | +6.1% | 0.08% | -4.7% |
| Q3 2016 | $101,699,000 | -2.1% | 3,197,082 | -0.1% | 0.09% | -2.3% |
| Q2 2016 | $103,923,000 | +37.8% | 3,201,615 | +18.7% | 0.09% | +35.4% |
| Q1 2016 | $75,439,000 | +30.1% | 2,698,066 | +65.9% | 0.06% | +32.7% |
| Q4 2015 | $57,976,000 | -45.9% | 1,626,247 | -49.8% | 0.05% | +2.1% |
| Q3 2015 | $107,116,000 | -15.3% | 3,239,074 | +7.2% | 0.05% | -53.8% |
| Q2 2015 | $126,499,000 | +37.9% | 3,020,512 | +7.3% | 0.10% | +38.7% |
| Q1 2015 | $91,713,000 | +8.9% | 2,814,149 | +6.1% | 0.08% | +4.2% |
| Q4 2014 | $84,245,000 | +30.2% | 2,653,382 | +1.5% | 0.07% | +22.0% |
| Q3 2014 | $64,706,000 | +118.2% | 2,613,343 | +99.1% | 0.06% | +118.5% |
| Q2 2014 | $29,654,000 | -0.9% | 1,312,725 | +6.7% | 0.03% | -3.6% |
| Q1 2014 | $29,921,000 | +28.3% | 1,229,809 | +31.8% | 0.03% | +27.3% |
| Q4 2013 | $23,315,000 | – | 932,993 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 474,741 | $7,557,877 | 7.35% |
| Finepoint Capital LP | 1,176,830 | $18,735 | 6.06% |
| Baker Brothers Advisors | 41,923,486 | $667,421,897 | 4.01% |
| Palo Alto Investors LP | 2,376,369 | $37,831,794 | 3.23% |
| EcoR1 Capital, LLC | 5,991,479 | $95,384,346 | 2.90% |
| Birchview Capital, LP | 249,400 | $3,970 | 2.80% |
| Ikarian Capital, LLC | 325,000 | $5,174,001 | 1.25% |
| Bain Capital Life Sciences Investors, LLC | 701,402 | $11,166 | 1.25% |
| RTW INVESTMENTS, LP | 3,670,938 | $58,441,333 | 1.19% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,048,750 | $16,696,100 | 1.03% |